Comparable renovascular protective effects of moxonidine and simvastatin in rats exposed to cigarette smoke

Vascular Pharmacology

Volumn 53, Issue 1-2, 2010, Pages 53-60

  Nasr, Magda A ^a   El gowilly, Sahar M ^a   El Mas, Mahmoud M ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Cigarette smoke; Isolated perfused kidney; Moxonidine; Nephrotoxicity; Simvastatin

Indexed keywords

ANTIOXIDANT; CARBACHOL; CATALASE; CHOLESTEROL; CIGARETTE SMOKE; CREATININE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN; ISOPRENALINE; LIPID; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MOXONIDINE; N(G) NITROARGININE; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE; PAPAVERINE; PHENYLEPHRINE; SIMVASTATIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UREA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; ISOLATED KIDNEY; KIDNEY BLOOD VESSEL; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; UREA BLOOD LEVEL; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; HYPOLIPIDEMIC AGENTS; IMIDAZOLES; KIDNEY FUNCTION TESTS; LIPIDS; MALE; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; SIMVASTATIN; TOBACCO SMOKE POLLUTION; VASODILATION;

EID: 77952431166     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2010.03.006     Document Type: Article

References (68)

1. Amann K., Rump L.C., Simonaviciene A., Oberhauser V., Wessels S., Orth S.R., Gross M.L., Koch A., Bielenberg G.W., Van Kats J.P., Ehmke H., Mall G., and Ritz E. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J. Am. Soc. Nephrol. 11 (2000) 1469-1478
2. Ashakumary L., and Vijayammal P.L. Effect of nicotine on lipoprotein metabolism in rats. Lipids 32 (1997) 311-315
3. Baigent C., Landray M., and Warren M. Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. Curr. Opin. Nephrol. Hypertens. 13 (2004) 601-605
4. Barthelmebs M., Wiernsperger N., Krieger J.P., Rapin J.R., Radziuk J., Grima M., and Imbs J.I. Mild acute renal failure potentiates metformin accumulation in the diabetic rat kidney without further impairment of renal function. Diabetes Metab. 29 (2003) 163-170
5. Barua R.S., Ambrose J.A., Eales-Reynolds L.J., DeVoe M.C., Zervas J.G., and Saha D.C. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation 104 (2001) 1905-1910
6. Bohmann C., Schollmeyer P., and Rump L.C. Effects of imidazolines on noradrenaline release in rat isolated kidney. Naunyn Schmiedebergs Arch. Pharmacol. 349 (1994) 118-124
7. Brawley L., Shaw A.M., and MacDonald A. Role of endothelium/nitric oxide in atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta. Eur. J. Pharmacol. 398 (2000) 285-296
8. In: Burtis C.A., and Ashwood E.R. (Eds). Tietz Fundamentals of Clinical Chemistry. 5th ed (2001), W.B. Saunders Co 486-488
9. Celermajer D.S., Adams M.R., Clarkson P., Robinson J., McCredie R., Donald A., and Deanfield J.E. Passive smoking and impaired endothelium dependent arterial dilatation in healthy young adults. N. Engl. J. Med. 334 (1996) 150-154
10. Chade A.R., Rodriguez-Porcel M., Grande J.P., Krier J.D., Lerman A., Romero J.C., Napoli C., and Lerman L.O. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation 106 (2002) 1165-1171
11. Chao H.M., Chidlow G., Melena J., Wood J.P., and Osborne N.N. An investigation into the potential mechanisms underlying the neuroprotective effect of clonidine in the retina. Brain Res. 877 (2000) 47-57
12. Chiu D.T.Y., Stults F.H., and Tappel A.L.L. Purification and solubility of rat lung soluble glutathione peroxidase. Biochem. Biophys. Acta. 445 (1976) 558-566
13. Cigremis Y., Turkoz Y., Akgoz M., and Sozmen M. The effects of chronic exposure to ethanol and cigarette smoke on the level of reduced glutathione and malondialdehyde in rat kidney. Urol. Res. 32 (2004) 213-218
14. Clairborne A. Catalase activity. In: Greenwald R.A. (Ed). Handbook of Methods for Oxygen Radical Research (1985), CRC Press, Boca Raton, Fla 283-284
15. Cooper R.G. Effect of tobacco smoking on renal function. Indian J. Med. Res. 124 (2006) 261-268
16. Derosa G., Cicero A.F., D'Angelo A., Fogari E., Salvadeo S., Gravina A., Ferrari I., Fassi R., and Fogari R. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. Clin. Ther. 29 (2007) 602-610
17. Dhalla N.S., Temsah R.M., and Netticadan T. Role of oxidative stress in cardiovascular diseases. J. Hypertens. 18 (2000) 655-673
18. Earle K.A., Harry D., Madhavi M., Zitouni K., and Barron J. Nitric oxide bioavailability and its potential relevance to the variation in susceptibility to the renal and vascular complications in patients with type 2 diabetes. Diabetes Care 32 (2009) 138-140
19. Ejerblad E., Fored C.M., Lindblad P., Fryzek J., Dickman P.W., Elinder C.G., McLaughlin J.K., and Nyre ́n O. Association between smoking and chronic renal failure in a nationwide population-based case-control study. J. Am. Soc. Nephrol. 15 (2004) 2178-2185
20. El-Mas M.M., Afify E.A., Omar A.G., Mohy El-Din M.M., and Sharabi F.M. Testosterone depletion contributes to cyclosporine-induced chronic impairment of acetylcholine renovascular relaxations. Eur. J. Pharmacol. 468 (2003) 217-224
21. 1-dopaminergic receptor mediates cyclosporine-SKF38393 renovascular interaction. Can. J. Physiol. Pharmacol. 83 (2005) 1129-1136
22. El-Mas M.M., Mohy El-Din M.M., El-gowilly S.M., and Sharabi F.M. Regional and endothelial differences in the cyclosporine attenuation of adenosine receptor-mediated vasorelaxations. J. Cardiovasc. Pharmacol. 43 (2004) 562-573
23. El-Mas M.M., Sharabi F.M., El-gowilly S.M., and Mohy El-Din M.M. Inhibition of nitric oxide-guanylate cyclase-dependent and -independent signaling contributes to impairment of β-adrenergic vasorelaxations by cyclosporine. Biochem. Pharmacol. 73 (2007) 359-367
24. 1-imidazoline sites. J. Pharmacol. Exp. Ther. 264 (1993) 172-182
25. Ferro A. Statins and vascular protection: a 'radical' view. J. Hypertens 20 (2002) 359-361
26. Freeman D.J., Caslake M.J., Griffin B.A., Hinnie J., Tan C.E., Watson T.D., Packard C.J., and Shepherd J. The effect of smoking on post-heparin lipoprotein and hepatic lipase, cholesteryl ester transfer protein and lecithin:cholesterol acyl transferase activities in human plasma. Eur. J. Clin. Invest. 28 (1998) 584-491
27. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low density cholesterol in plasma without use of preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
28. Gilks B., Price K., Wright J.L., and Churg A. Antioxidant gene expression in rat lung after exposure to cigarette smoke. Am. J. Pathol. 152 (1998) 269-278
29. Giroux L.M., Davignon J., and Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim. Biophys. Acta 1165 (1993) 335-338
30. Greven J., and von Bronewski-Schwarzer B. Site of action of moxonidine in the rat nephron. Naunyn Schmiedebergs Arch. Pharmacol. 364 (2001) 496-500
31. Hucks D., Thuraisingham R.C., Raftery M.J., and Yaqoob M.M. Homocysteine induced impairment of nitric oxide-dependent vasorelaxation is reversible by the superoxide dismutase mimetic TEMPOL. Nephrol. Dial. Transplant. 19 (2004) 1999-2005
32. Hutchison S.J., Reitz M.S., Sudhir K., Sievers R.E., Zhu B.Q., Sun Y.P., Chou T.M., Deedwania P.C., Chatterjee K., Glantz S.A., and Parmley W.W. Chronic dietary L-arginine prevents endothelial dysfunction secondary to environmental tobacco smoke in normocholesterolemic rabbits. Hypertension 29 (1997) 1186-1191
33. Hutchison S.J., Sudhir K., Sievers R.E., Zhu B.Q., Sun Y.P., Chou T.M., Chatterjee K., Deedwania P.C., Cooke J.P., Glantz S.A., and Parmley W.W. Effects of L-arginine on atherogenesis and endothelial dysfunction due to secondhand smoke. Hypertension 34 (1999) 44-50
34. Jaimes E.A., DeMaster E.G., Tian R.X., and Raij L. Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1031-1036
35. Jessup W., Kritharides L., and Stocker R. Lipid oxidation in atherogenesis: an overview. Biochem. Soc. Trans. 32 Pt 1 (2004) 134-138
36. Johnson A.M. Amino acids, peptides and proteins. In: Burtis C.A., Ashwood E.R., and Bruns D.E. (Eds). Tietz Textbook of Clinical Chemistry and Molecular Diagnosis. 4th ed. (2006), WB Saunders, Missouri, USA 588-589
37. Karmen N.B. Oxidative modification of erythrocyte membranes in the acute stage of severecraniocerebral trauma and its correction with clonidine. Bull. Exp. Biol. Med. 136 (2003) 362-365
38. Kasiske B.L., O'Donnell M.P., Garvis W.J., and Keane W.F. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ. Res. 62 (1988) 367-374
39. Kinnula V.L. Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases. Thorax 60 (2005) 693-700
40. Koomans H.A., Blankestijn P.J., and Joles J.A. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J. Am. Soc. Nephrol. 153 (2004) 524-537
41. Latha M.S., Vijayammal P.L., and Kurup P.A. Effect of nicotine administration on lipid metabolism in rats. Indian J. Med. Res. 98 (1993) 44-49
42. Lee J.H., Lee D.S., Kim E.K., Choe K.H., Oh Y.M., Shim T.S., Kim S.E., Lee Y.S., and Lee S.D. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am. J. Respir. Crit. Care Med. 172 (2005) 987-993
43. Marklund S., and Marklund G. Involvement of superoxide anion radical in autooxidation of pyrogallol and a convenient assay for SOD. Eur. J. Biochem. 47 (1974) 469-474
44. Moshage H., Kok B., Huizenga J.R., and Jansen P.L. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin. Chem. 41 (1995) 892-896
45. Mukaddam-Daher S., and Gutkowska J. Atrial natriuretic peptide is involved in renal actions of moxonidine. Hypertension 35 (2000) 1215-1220
46. Navarro-Antolín J., Redondo-Horcajo M., Zaragoza C., Alvarez-Barrientos A., Fernández A.P., León-Gómez E., Rodrigo J., and Lamas S. Role of peroxynitrite in endothelial damage mediated by Cyclosporine A. Free Radic. Biol. Med. 42 (2007) 394-403
47. Neufeld E.J., Mietus-Snyder M., Beiser A.S., Baker A.L., and Newburger J.W. Passive cigarette smoking and reduced HDL cholesterol levels in children with high-risk lipid profiles. Circulation 96 (1997) 1403-1407
48. Neumann J., Ligtenberg G., Oey L., Koomans H.A., and Blankestijn P.J. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J. Am. Soc. Nephrol. 15 (2004) 2902-2907
49. Ohkawa H., Ohishi N., and Yagi K. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 (1979) 351-358
50. Orth S.R. Smoking and the kidney. J. Am. Soc. Nephrol. 13 (2002) 1663-1672
51. Pinto-Sietsma S.J., Mulder J., Janssen W.M., Hillege H.L., de Zeeuw D., and de Jong P.E. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann. Intern. Med. 133 (2000) 585-591
52. Richardson R.J., and Murphy S.D. Effect of glutathione depletion on tissue deposition of methyl mercury in rats. Toxicol. Appl. Pharmacol. 31 (1975) 505-519
53. Ritter J.M. Nebivolol: endothelium-mediated vasodilating effect. J. Cardiovasc. Pharmacol. 38 Suppl 3 (2001) S13-S16
54. Rueckschloss U., Galle J., Holtz J., Zerkowski H.R., and Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 104 (2001) 1767-1772
55. Schlatter E., Ankorina-Stark I., Haxelmans S., and Hohage H. Moxonidine inhibits Na+/H + exchange in proximal tubule cells and cortical collecting duct. Kidney Int. 52 (1997) 454-459
56. Schwarzacher S.P., Hutchison S., Chou T.M., Sun Y.P., Zhu B.Q., Chatterjee K., Glantz S.A., Deedwania P.C., Parmley W.W., and Sudhir K. Antioxidant diet preserves endothelium-dependent vasodilatation in resistance arteries of hypercholesterolemic rabbits exposed to environmental tobacco smoke. J. Cardiovasc. Pharmacol. 31 (1998) 649-653
57. Singh A., Rangasamy T., Thimmulappa R., Lee H., Osburn W., Brigelius-Flohe R., Kensler T., and Biswal S. Glutathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2. Am. J. Respir. Cell Mol. Biol. 35 (2006) 639-650
58. Smyth D.D., and Penner S.B. Imidazoline receptor mediated natriuresis: central and/or peripheral effect?. J. Auton. Nerv. Syst. 72 (1998) 155-162
59. Strojek K., Grzeszczak W., Górska J., Leschinger M.I., and Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy?. J. Am. Soc. Nephrol. 12 (2001) 602-605
60. Tuncer M., and Vanhoutte P.M. Response to the endothelium-dependent vasodilator acetylcholine in perfused kidneys of normotensive and spontaneously hypertensive rats. Blood Press. 2 (1993) 217-220
61. 1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine. J. Hypertens 15 (1997) 117-125
62. Vanisree A.J., and Sudha N. Curcumin combats against cigarette smoke and ethanol-induced lipid alterations in rat lung and liver. Mol. Cell. Biochem. 288 (2006) 115-123
63. Velliquette R.A., and Ernsberger P. Contrasting metabolic effects of antihypertensive agents. J. Pharmacol. Exp. Ther. 307 (2003) 1104-1111
64. Warmoth L., Regalado M.M., Simoni J., Harrist R.B., and Wesson D.E. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. Am. J. Med. Sci. 330 (2005) 111-119
65. Wilson S.H., Chade A.R., Feldstein A., Sawamura T., Napoli C., Lerman A., and Lerman L.O. Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. Nephrol. Dial. Transplant. 18 (2003) 703-709
66. Yamaguchi Y., Haginaka J., Morimoto S., Fujioka Y., and Kunitomo M. Facilitated nitration and oxidation of LDL in cigarette smokers. Eur. J. Clin. Invest. 35 (2005) 186-193
67. Yamaguchi Y., Nasu F., Harada A., and Kunitomo M. Oxidants in the gas phase of cigarette smoke pass through the lung alveolar wall and raise systemic oxidative stress. J. Pharmacol. Sci. 103 (2007) 275-282
68. Zoccali C. Endothelial dysfunction and the kidney. Emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J. Am. Soc. Nephrol. 17 4 Suppl 2 (2006) S61-S63